Ki-67 labeling: A more sensitive indicator of malignant phenotype than mitotic count or tumor size?

Journal of Surgical Oncology

Volumn 106, Issue 6, 2012, Pages 724-727

  Lowe, Kevin ^a   Khithani, Amit ^a   Liu, Elizabeth ^a   Winston, Tanyss ^a   Christian, Derrick ^a   Saad, Joe ^a   Jeyarajah, Dhiresh Rohan ^a  

^a METHODIST DALLAS MEDICAL CENTER   (United States)

Author keywords

lymph node metastases; malignant phenotype; pancreatic neuroendocrine tumors

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MITOSIS; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOSIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHENOTYPE;

EID: 84867891019     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23124     Document Type: Article

References (16)

1. Ãberendorfer S:, Karzinoide tumoren des Dünndarms. Frankf Z Pathol 1907; 1: 426-432.
2. IARC: Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs. Lyon: International agency for research on cancer; 2004.
3. Hemminki K, Li X:, Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.
4. Soga J, Soga J:, Carcinoids of the pancreas: An analysis of 156 cases. Cancer 2005; 104: 1180-1187.
5. Modlin IM, Moss SF, Chung DC, et al.: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008; 100: 1282-1289.
6. Klöppel G, Perren A, Heitz P, et al.: The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27.
7. Rindi G, Klöppel G, Alhman H, et al.: TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Archiv 2006; 449: 395-401.
8. Brown DC, Gatter KC:, Ki67 protein: The immaculate deception ? Histopathology 2002; 40: 2-11.
9. Sobin LH GM, Gospodarowicz MK, Wittekind C, editors. Digestive system tumors. UICC: TNM classification of malignant tumours. Oxford: Wiley-Blackwell; 2009.
10. Klimstra DS, Modlin IR, Adsay NV, et al.: Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34: 300-313.
11. Gentil Perret A, Mosnier JF, Buono JP, et al.: The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am J Clin Pathol 1998; 109: 286-293.
12. Ekeblad S, Skogseid B, Dunder K, et al.: Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 7798-7803.
13. Pape UF, Böhmig M, Berndt U, et al.: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci 2004; 1014: 222-233.
14. Schmitt AM, Anlauf M, Rousson V, et al.: WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007; 31: 1677-1682.
15. Pape UF, Jann H, Müller-Nordhorn J, et al.: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265.
16. Scarpa A, Mantovani W, Capelli P, et al.: Pancreatic endocrine tumors: Improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 824-833.